Poland· PL-100485451

Artelac

A künstliche tränenflüssigkeit und sonstige indifferente präparate product containing hypromellosum, registered in Poland by Delfarma Sp. z o.o.. The same ATC class is registered in 11 of our 19 countries.

ATC S01XA20

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedArtelacATCS01XA20REGISTER NO.PL-100485451PACKS LISTED1CHECKEDSeptember 27, 2026

Where it is registered

Künstliche tränenflüssigkeit und sonstige indifferente präparate is registered in 11 of 19 countries.

Countries holding a registration under ATC S01XA20 (künstliche tränenflüssigkeit und sonstige indifferente präparate), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 7 of them publish a price we can compare per daily dose

Künstliche tränenflüssigkeit und sonstige indifferente präparate · ATC S01XA20

11 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

URPL (Poland)
Active substance
Hypromellosum
Manufacturer
Delfarma Sp. z o.o.
Country
Poland (PL)
ATC code
S01XA20
ATC class
Künstliche Tränenflüssigkeit und sonstige indifferente Präparate
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 1

  • gtin
    05909991518240

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Künstliche tränenflüssigkeit und sonstige indifferente präparate in 13 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All künstliche tränenflüssigkeit und sonstige indifferente präparate products

Authorised across Europe · EMA

The same active substance is authorised in 19 EEA countries. Names it is sold under:

  • Austria · Hypromellose Agepha, Prosicca
  • Bulgaria · Артелак, Кристал Вижън
  • Germany · Artelac, Artelac Edo
  • Denmark · Artelac, Hyprosan
  • Estonia · Artelac, Hyprosan
  • Spain · Artific
  • Finland · Artelac, Hyprosan
  • France · Artelac
  • United Kingdom (Northern Ireland) · Hypromellose Fdc International, Hypromellose Martindale Pharmaceuticals
  • Greece · Lubrilac, Vidilac
  • Ireland · Artelac, Artelac Preservative Free Single Dose Unit
  • Iceland · Hyprosan
  • Lithuania · Artelac
  • Luxembourg · Artelac, Artelac Edo
  • Netherlands · Artelac, Artelac Edo
  • Norway · Artelac, Hyprosan
  • Portugal · Davilose, Davilose Forte
  • Sweden · Artelac, Hyprosan
  • Slovenia · Artelac, Artelac Uno

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/4f4ec9ef-8b3f-43cc-9709-9025dab8c8d9
GET /v1/drugs/4f4ec9ef-8b3f-43cc-9709-9025dab8c8d9?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Krople do oczu, roztwór",
  "source": "urpl",
  "strength": "3,2 mg/ml",
  "packaging": "05909991518240 ¦ OTC ¦ 150692\n1 butelka 10 ml",
  "substance": "Hypromellosum 3.2 mg/ml",
  "common_name": "Hypromellosum",
  "pl_product_id": "100485451",
  "pozwolenie_nr": "136/23",
  "auth_procedure": "IR",
  "authorisation_validity": "2028-07-13"
}

See everything about künstliche tränenflüssigkeit und sonstige indifferente präparate.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.